GDA-401

GDA-401 is an investigational **genetically engineered natural killer cell therapy** being developed by Gamida Cell for cancer, particularly solid tumors. Publicly available information indicates it belongs to Gamida Cell's preclinical NK-cell pipeline that uses **CAR- and CRISPR-mediated engineering strategies** intended to improve tumor targeting, potency, and persistence, but the specific construct, antigen target, and detailed mechanism for GDA-401 itself have not been publicly disclosed. Based on the available evidence, it should be characterized as a preclinical allogeneic NK-cell immunotherapy program rather than an approved or clinically validated drug product.